Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 52

Sort by

Sort Order Select

Journal Articles

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

Blood (2024) 143 (25): 2612–2626.

https://doi.org/10.1182/blood.2023022777

Published: 2024

Includes: Supplemental data

Journal Articles

RAD51 Is Required for the Occupancy of Replication Licensing Factors on the Myeloma Genome

Jiangning Zhao, Srikanth Talluri, Subodh Kumar, Eugenio Morelli, Lakshmi B. Potluri, Masood A. Shammas, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 6587.

https://doi.org/10.1182/blood-2023-189307

Published: 2023

Journal Articles

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

Maria Luisa Guerrera, Zachary R Hunter, Kris Richardson, Nickolas Tsakmaklis, Amanda Kofides, Shirong Liu, Christopher J Patterson, Eugenio Morelli, Jorge J. Castillo, Shayna R Sarosiek, Catherine A. Flynn, Kirsten Meid, Andrew R. Branagan, Ruben D. Carrasco, Kenneth C. Anderson, Nikhil C Munshi, Steven P Treon, Xia Liu

Blood (2023) 142 (Supplement 1): 3303.

https://doi.org/10.1182/blood-2023-190880

Published: 2023

Journal Articles

CRISPR-Based Functional Transcriptomics Defines the Tumor-Dependency and Molecular Determinants of Long Noncoding RNAs in Multiple Myeloma

Eugenio Morelli, Anil Aktas-Samur, Domenico Maisano, Claire Gao, Na Liu, Vanessa Favasuli, Marcello Turi, Pietro Folino, Mariateresa Fulciniti, Annamaria Gulla, Kenneth C. Anderson, Mehmet K. Samur, Nikhil C Munshi

Blood (2023) 142 (Supplement 1): 640.

https://doi.org/10.1182/blood-2023-185523

Published: 2023

Journal Articles

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

Blood (2023) 141 (23): 2841–2852.

https://doi.org/10.1182/blood.2022018885

Published: 2023

Includes: Supplemental data

Journal Articles

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

Blood (2023) 141 (4): 391–405.

https://doi.org/10.1182/blood.2022016892

Published: 2023

Includes: Supplemental data

Journal Articles

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Yao Yao, Jessica Fong Ng, Woojun D Park, Mehmet K. Samur, Eugenio Morelli, Nicholas P Kwiatkowski, Jessica Encinas Mayoral, Zuzana Chyra, Yan Xu, Behnam Nabet, Marta Chesi, Nathaniel Gray, Richard A. Young, Kenneth C. Anderson, Charles Y Lin, Nikhil C Munshi, Mariateresa Fulciniti

Blood (2022) 140 (Supplement 1): 9955–9956.

https://doi.org/10.1182/blood-2022-163811

Published: 2022

Journal Articles

Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma

Annamaria Gulla, Eugenio Morelli, Mehmet K. Samur, Megan Johnstone, Cirino Botta, Delaney Vinaixa, Marcello Turi, Mariateresa Fulciniti, Kenneth Wen, Selma Cifric, Srikanth Talluri, Giada Bianchi, Rao Prabhala, Paul G. Richardson, Dharminder Chauhan, Ruben D. Carrasco, Teru Hideshima, Nikhil C Munshi, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 7114–7115.

https://doi.org/10.1182/blood-2022-162653

Published: 2022

Journal Articles

BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells

Keiji Kurata, Mehmet K. Samur, Priscilla Liow, Kenneth Wen, Leona Yamamoto, Jiye Liu, Eugenio Morelli, Annamaria Gulla, Yu-Tzu Tai, Jun Qi, Teru Hideshima, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 596–597.

https://doi.org/10.1182/blood-2022-162445

Published: 2022

Journal Articles

Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma

Jiye Liu, Lijie Xing, Teru Hideshima, Keiji Kurata, Mehmet K. Samur, Eugenio Morelli, Kenneth Wen, Nikhil C Munshi, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 360–361.

https://doi.org/10.1182/blood-2022-164901

Published: 2022

Journal Articles

Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 1551–1552.

https://doi.org/10.1182/blood-2022-167604

Published: 2022

Journal Articles

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

Blood (2022) 140 (Supplement 1): 1549–1550.

https://doi.org/10.1182/blood-2022-169863

Published: 2022

Journal Articles

PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment

Tengteng Yu, Mu Hao, Hailin Chen, Kenneth Wen, Tingjian Wang, Thomas C.M Smits, Mehmet K. Samur, Eugenio Morelli, Lijie Xing, Liang Lin, Jun Qi, Gang An, Nikhil C Munshi, Yu-Tzu Tai, Lugui Qiu, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 854–855.

https://doi.org/10.1182/blood-2022-159137

Published: 2022

Journal Articles

Long Noncoding RNA LINC01410 Interacts with the Minichromosome Maintenance (MCM) Complex to Promote Tumor Cell Growth in Multiple Myeloma

Doriana Gramegna, Na Liu, Yao Yao, Megan Johnstone, Domenico Maisano, Annamaria Gulla, Anil Aktas-Samur, Aldo Roccaro, Mehmet K. Samur, Mariateresa Fulciniti, Eugenio Morelli, Nikhil C Munshi

Blood (2022) 140 (Supplement 1): 4191–4192.

https://doi.org/10.1182/blood-2022-169185

Published: 2022

Journal Articles

Gabarap Loss Mediates Immune Escape in High Risk Multiple Myeloma

Annamaria Gulla, Eugenio Morelli, Mehmet K. Samur, Cirino Botta, Megan Johnstone, Giada Bianchi, Mariateresa Fulciniti, Leona Yamamoto, Rao Prabhala, Kenneth Wen, Paul G. Richardson, Yu-Tzu Tai, Dharminder Chauhan, Teru Hideshima, Nikhil C. Munshi, Kenneth C. Anderson

Blood (2021) 138 (Supplement 1): 891.

https://doi.org/10.1182/blood-2021-148621

Published: 2021

Journal Articles

Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma

Blood (2021) 138 (Supplement 1): 894.

https://doi.org/10.1182/blood-2021-151705

Published: 2021

Journal Articles

Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells

Leona Yamamoto, Sanika Derebail, Anil Aktas-Samur, Teru Hideshima, Zuzana Chyra, Chandraditya Chakraborty, Yao Yao, Doriana Gramegna, Eugenio Morelli, Mehmet K. Samur, Jing Deng, Yifan Zhai, Annamaria Gulla, Mariateresa Fulciniti, Kenneth C. Anderson, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2655.

https://doi.org/10.1182/blood-2021-149530

Published: 2021

Journal Articles

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Zuzana Chyra, Mehmet K. Samur, Anil Aktas-Samur, Yao Yao, Sanika Derebail, Tommaso Perini, Yan Xu, Eugenio Morelli, Sophia Adamia, Woojun D Park, Lin Charles, Ryosuke Shirasaki, Masood A. Shammas, Constantine S. Mitsiades, Roman Hajek, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2670.

https://doi.org/10.1182/blood-2021-152121

Published: 2021

Journal Articles

Universally Observed Loss of BCL7A Allows Activation of IRF4 and Its Transcriptional Activity in Multiple Myeloma Cells

Chandraditya Chakraborty, Srikanth Talluri, Eugenio Morelli, Sanika Derebail, Yao Yao, Yan Xu, Alba Rodríguez García, María Linares, Kenneth C. Anderson, Moritz Binder, Mehmet K. Samur, Mariateresa Fulciniti, Nikhil C. Munshi

Blood (2021) 138 (Supplement 1): 2667.

https://doi.org/10.1182/blood-2021-153462

Published: 2021

Journal Articles

Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability

Yao Yao, Woojun D Park, Eugenio Morelli, Mehmet K. Samur, Nicholas P Kwiatkowski, Ryosuke Shirasaki, Yan Xu, Chandraditya Chakraborty, Behnam Nabet, Marta Chesi, Nathaniel Gray, Richard A. Young, Kenneth C. Anderson, Constantine S. Mitsiades, Lin Charles, Nikhil C. Munshi, Mariateresa Fulciniti

Blood (2021) 138 (Supplement 1): 2687.

https://doi.org/10.1182/blood-2021-153469

Published: 2021

NARROW

Loss of GABARAP mediates resistance to immunogenic chemotherapy in multiple myeloma

RAD51 Is Required for the Occupancy of Replication Licensing Factors on the Myeloma Genome

Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth

CRISPR-Based Functional Transcriptomics Defines the Tumor-Dependency and Molecular Determinants of Long Noncoding RNAs in Multiple Myeloma

CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma

A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth

CDK7 Inhibition Targets Proliferative and Metabolic Oncogenic Vulnerabilities in Multiple Myeloma

Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma

BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells

Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma

Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia

PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment

Long Noncoding RNA LINC01410 Interacts with the Minichromosome Maintenance (MCM) Complex to Promote Tumor Cell Growth in Multiple Myeloma

Gabarap Loss Mediates Immune Escape in High Risk Multiple Myeloma

Identifying Long Noncoding RNA Dependencies Using CRISPR Interference (CRISPRi)-Based Platform in Multiple Myeloma

Dual BCL-2/BCL-XL Inhibitor Pelcitoclax (APG-1252) Overcomes Intrinsic and Acquired Resistance to Venetoclax in Multiple Myeloma Cells

B Cell Transcriptional Coactivator POU2AF1 (BOB-1) Is an Early Transcription Factor Modulating the Protein Synthesis and Ribosomal Biogenesis in Multiple Myeloma: With Therapeutic Implication

Universally Observed Loss of BCL7A Allows Activation of IRF4 and Its Transcriptional Activity in Multiple Myeloma Cells

Aberrant CDK7 Activity Drives the Cell Cycle and Transcriptional Dysregulation to Support Multiple Myeloma Growth: An Attractive Molecular Vulnerability

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only